What is Bausch + Lomb's 2027?

Bausch + Lomb (BLCO) reported 2027 of $222M in Q1 2026.

How has Bausch + Lomb's 2027 changed year-over-year?

Bausch + Lomb's 2027 increased by 1.4% year-over-year, from $219M to $222M.

Bausch + Lomb BLCO 2027

2027 at other companies

The Cooper Companies, Inc.COO

——

Tarsus Pharmaceuticals, Inc.TARS

——

SolventumSOLV

——

PBH

Prestige Consumer HealthcarePBH

——

Mirum Pharmaceuticals, Inc.MIRM

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$1.2B+9.4%

Operating income$33.0M+140%

Net income-$71.0M+66.5%

EPS (diluted)-$0.20+66.7%

Balance sheet

See full

Cash & equivalents$279.0M+29.8%

Total debt$5.0B+4.3%

Total equity$6.4B+0.3%

Total assets$13.8B+2.6%

Cash flow

See full

Operating cash flow$32.0M+228%

CapEx$100.0M-9.1%

Free cash flow-$68.0M+49.6%

Valuation

See full

Market cap$5.43B+10.2%

Profitability

See full

Operating margin4.4%+2.9pp

Net margin-4.2%-1.3pp

FCF margin-3.4%0.0pp

Returns & leverage

See full

Return on equity-3.4%-0.9pp

Debt / equity0.8×0.0×

Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bausch + Lomb's 2027?: Bausch + Lomb (BLCO) reported 2027 of $222M in Q1 2026.
How has Bausch + Lomb's 2027 changed year-over-year?: Bausch + Lomb's 2027 increased by 1.4% year-over-year, from $219M to $222M.